Story

 - 

French MPs reject drug price reviews five years after initial price-setting proposal

PARIS, 25 Oct (APM) - French MPs have voted against a proposal to systematically review drug prices five years after being set.
The National Assembly's social affairs commission supported an amendment to the 2020 social security funding bill (PLFSS) presented by the general rapporteur, Olivier Véran when it examined the text last week.
''Inspired'' by the France Assos Santé patient association, it would have modified the social security code, indicating that drug prices must be reviewed no later than five years after being set initially. (APMHE 64773).
''We are all in favour of regularly reviewing drug prices. We share this aim,'' said French health minister Agnès Buzyn on Thursday evening before pointing out that currently, more than half of drugs see their prices reviewed after less than five years.
''In practice, CEPS [French healthcare products pricing committee] negotiates regular price cuts, according to a sometimes very abridged timescale…laying out a maximum time period in the law would lead pharmaceutical companies to consider it as a reference time period and refuse all price cuts'' before five years had elapsed, she said.
The 2020 PLFSS is currently going from the National Assembly.
vg/hg/nh

[HG4PZXMR6]

TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT

Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.